An eight-week double-blind, multi-center, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren 75mg, 150mg and 300mg in elderly patients with essential hypertension when given a light meal

Phase 3

Completed

• Conditions: hypertension; increased blood pressure; 10057166

• Registration Number: NL-OMON31913
• Lead Sponsor: ovartis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 124

Inclusion Criteria

The mean sitting systolic blood pressure should be between 150 and 180 mm Hg mercury at randomisation (visit 3).

Exclusion Criteria

Severe hypertension (mean sitting diastolic blood pressure above or equal 110 mm Hg and/or mean sitting systolic blood pressure above or equal 180 mm Hg.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Blood pressure (msSBP).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Blood pressure (msSBP/msDBP).<br /><br>- Lab evaluations.<br /><br>- Physical examinations.</p><br>